A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

J Kellogg Parsons; Peter A Pinto; Christian P Pavlovich; Edward Uchio; Hyung L Kim; Mikel N Nguyen; James L Gulley; Christina Jamieson; Paul Hsu; Margarita Wojtowicz; Howard Parnes; Jeffrey Schlom; William L Dahut; Ravi A Madan; Renee N Donahue; H-H Sherry Chow

doi:10.1016/j.euf.2018.08.016

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

Eur Urol Focus. 2018 Sep;4(5):636-638. doi: 10.1016/j.euf.2018.08.016. Epub 2018 Sep 7.

Authors

J Kellogg Parsons¹, Peter A Pinto², Christian P Pavlovich³, Edward Uchio⁴, Hyung L Kim⁵, Mikel N Nguyen⁶, James L Gulley², Christina Jamieson⁷, Paul Hsu⁸, Margarita Wojtowicz², Howard Parnes², Jeffrey Schlom², William L Dahut², Ravi A Madan², Renee N Donahue², H-H Sherry Chow⁸

Affiliations

¹ Department of Urology, UC San Diego Moores Cancer Center, La Jolla, CA, USA. Electronic address: jkparsons@ucsd.edu.
² National Cancer Institute, Bethesda, MD, USA.
³ Department of Urology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
⁴ Department of Urology, UC Irvine, Orange, CA, USA.
⁵ Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁶ Department of Urology, University of Southern California, Los Angeles, CA, USA.
⁷ Department of Urology, UC San Diego Moores Cancer Center, La Jolla, CA, USA.
⁸ University of Arizona Cancer Center, Tucson, AZ, USA.

Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5mo. Final results will be available in 2019.

Trial registration: ClinicalTrials.gov NCT02326805.

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial
Research Support, N.I.H., Extramural

MeSH terms

Aged
Cancer Vaccines / administration & dosage
Cancer Vaccines / adverse effects
Cancer Vaccines / therapeutic use*
Disease Progression
Follow-Up Studies
Humans
Immunologic Factors / therapeutic use
Immunotherapy / methods*
Male
Middle Aged
Neoplasm Grading
Prostate-Specific Antigen / blood
Prostate-Specific Antigen / immunology
Prostatic Neoplasms / immunology
Prostatic Neoplasms / mortality
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy*
Treatment Outcome

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Associated data

Grants and funding